TrumpRx drug prices went live on February 5, 2026, delivering steep cuts on 40 branded medicines, including Wegovy at $149 a month and Ozempic at $350. Six months later, 17 manufacturers have signed Most-Favored-Nation (MFN) pricing deals covering an estimated 86% of the U.S. branded drug market. But a February Supreme Court ruling stripped the administration of the tariff authority that built the program, and most insured Americans still see no direct benefit. This guide explains what the platform actually delivers, who saves, and what changes from here.

TrumpRx Drug Prices in Practice: What Launched in February

TrumpRx.gov launched on February 5, 2026, roughly six weeks behind the administration's original January target. The platform features 40 brand-name medicines from the first five manufacturers to sign MFN deals: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.

The biggest visible savings are concentrated in GLP-1 drugs. The injectable Wegovy fell from a $1,349 monthly list price to as low as $199, with an average of $350. Ozempic dropped from $1,028 to an average of $350. The oral Wegovy pill, priced at $149 for the starting dose, represents an 89% reduction from list — the steepest cut on the platform. Zepbound was reduced from $1,088 to an average of $346.

The platform serves cash-pay and uninsured patients. Medicare beneficiaries access a separate negotiated price of $245 per month with a $50 patient copay for GLP-1 drugs, beginning mid-2026.

How MFN Pricing Works

The Most-Favored-Nation model ties U.S. prices to the lowest net price paid in a basket of comparable developed countries. The May 2025 executive order directed federal agencies to pressure manufacturers to align U.S. prices with peer-nation lows. Voluntary deals — not formal rulemaking — became the implementation path.

Each deal applies to two channels. Existing drugs receive MFN pricing through state Medicaid programs. New launches receive MFN pricing across Medicare, Medicaid, and commercial payers from day one. In exchange, manufacturers received three-year exemptions from pharmaceutical tariffs and incentives tied to U.S. manufacturing investment.

The agreements remain confidential. Public Citizen filed FOIA lawsuits in late 2025 against the Department of Health and Human Services and the Department of Commerce to compel disclosure of the deal text, which has not been publicly released.

Why This Matters Again Now

The tariff lever that drove the original deals is gone. On February 20, 2026, the Supreme Court ruled 6-3 in Learning Resources, Inc. v. Trump that the International Emergency Economic Powers Act does not authorize the president to impose tariffs. The administration responded with a 10% Section 122 tariff, later raised to 15%, but that authority expires on July 24, 2026, unless extended by Congress.

That changes the leverage equation. MFN deals signed before February were negotiated under the threat of a 100% pharmaceutical tariff if companies refused. Manufacturers still pending — including Johnson & Johnson and Regeneron — now face a far weaker stick.

The deals are not preventing broader price increases either. Reuters reported that at least 350 branded drugs raised prices in early 2026 — up from 250 the prior year — and several MFN signatories, including Pfizer and GSK, are among the companies raising other products. The cuts are real, but narrow.

The Industry Response: 17 Deals, Mixed Signals

By April 2026, 17 manufacturers had signed MFN deals, covering roughly 86% of the branded U.S. drug market. The list includes Pfizer, AstraZeneca, EMD Serono, Novo Nordisk, Eli Lilly, AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche), Gilead Sciences, GSK, Merck, Novartis, and Sanofi. AbbVie joined on January 12, 2026, with a $100 billion U.S. R&D and manufacturing commitment.

Pfizer's first-quarter 2026 results showed revenue of $14.45 billion, up 5.4% year-over-year and ahead of analyst estimates. The company reaffirmed full-year 2026 guidance of $59.5 to $62.5 billion in revenue, noting the outlook reflects the unfavorable impact of MFN pricing and TrumpRx.

The market read: negotiated rules beat open-ended threats. Pfizer shares closed at $25.48 on September 30, 2025, up 6.8% the day the original deal was announced — the stock's best session since October 2021. Investors have since priced policy risk into forward guidance rather than treating it as a wildcard.

Risks and What to Watch

Three uncertainties matter most through the rest of 2026.

The legal foundation is shifting. Without IEEPA tariffs, the administration's primary enforcement mechanism is the Section 232 national security tariff — a slower, more procedurally constrained tool. Codification through Congress — the "Great Healthcare Plan" unveiled on January 15, 2026 — faces opposition from more than 50 free-market organizations arguing MFN imports foreign price controls.

The Medicare expansion is in process. CMS proposed two new payment models in December 2025 — GLOBE for Part B and GUARD for Part D — that would apply international price benchmarks to roughly 25% of Medicare beneficiaries in trial regions starting in 2026 and 2027. Combined federal savings are estimated at $26 billion.

The commercial insurance gap remains. Roughly 155 million Americans with employer-sponsored coverage see no direct benefit from MFN deals. Whether that gap closes depends on legislation that has not yet moved through Congress.

TrumpRx delivered visible cuts on the drugs that drive the most U.S. spending — but on a narrower foundation than the original framework projected. The platform works for cash-paying patients on a limited list. The structural questions — whether MFN survives without tariff leverage, whether commercial insurance ever gets pulled in, and whether codification clears Congress before the midterms — define what 2027 looks like.

FAQ

What is TrumpRx and what does it cover? TrumpRx is a federal direct-to-consumer drug-purchasing platform launched February 5, 2026, at TrumpRx.gov. At launch it featured 40 brand-name medicines from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. The list expands as additional manufacturers reach MFN pricing deals with the administration.

Will insured patients save money on TrumpRx? Probably not directly. TrumpRx is a cash-pay channel. Patients with commercial insurance generally pay less through their plan's copay. Medicare beneficiaries access a separate $50-copay track for GLP-1 drugs at a $245 negotiated monthly price, beginning mid-2026.

How does the Supreme Court tariff ruling affect TrumpRx? The February 20, 2026 ruling in Learning Resources, Inc. v. Trump struck down the IEEPA tariff authority that pressured manufacturers into MFN deals. Existing deals remain in place, but new agreements now lack the same enforcement leverage, and codification through Congress remains uncertain.

How much do GLP-1 drugs cost through TrumpRx? The injectable Wegovy is priced as low as $199 a month (average $350), down from a $1,349 list price. Ozempic averages $350, down from $1,028. The oral Wegovy pill starts at $149 — the deepest discount on the platform. Zepbound averages $346, down from $1,088.

Sources and Further Reading